$HELP

Helus Pharma Inc.

Helus Pharma is a clinical-stage pharmaceutical company headquartered in Canada, developing proprietary neuro-serotonergic agents (NSAs), a subset of serotonergic agonists engineered to selectively activate serotonin receptor subtypes and signaling pathways. Its research and development strategy centers on platform technology, clinical programs and preclinical drug candidates. The pipeline includes HLP003, a deuterated psilocin molecule; HLP004, a deuterated version of DMT; and HLP005, phenethylamine and tryptamine derivatives. The company is conducting clinical development for potential mental health treatments, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder. Helus Pharma also develops EMBARK, a psychedelic facilitation training program for healthcare professionals and others interested in providing psychological support. It is operational in Canada, the United States, the United Kingdom, Poland, Greece, Australia, the Netherlands and Ireland.

3
1
7

No SEC Form 4 filings for $HELP in the last 30 days.

See all $HELP insider activity →
Med

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

Why is Helus Pharma stock tumbling today?

Helus Pharma (HELP) shares fell 25.4% in pre-market trading after reporting Phase 3 trial success for HLP003, a treatment for major depressive disorder, but missing Q2 earnings estimates by $0.68 per share. The stock declined despite meeting primary endpoints, with investors reacting to the earnings miss and broader market downturn.

HELP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 11 news stories mentioning HELP (Helus Pharma Inc.). Coverage has skewed bearish: 3 bullish, 1 neutral, and 7 bearish.

Recent HELP coverage spans financial news, earnings and insider activity.

What's driving HELP

  • Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

    biospace.com · Nov 16, 2026

  • Positive pivotal data is likely to push the stock higher as investors price in potential approval and market opportunity.

    rttnews.com · Nov 16, 2026

  • The earnings miss and mixed trial readout triggered strong selling pressure.

    investing.com · Nov 16, 2026

  • Pre‑data rally reflects optimism; results will dictate direction.

    finance.yahoo.com · Nov 16, 2026

  • Governance change may cause short‑term uncertainty, but upcoming trial data remains the primary catalyst.

    tradingview.com · Oct 27, 2026

AlphAI scores every news story that mentions HELP with an AI model for sentiment and relevance, and aggregates insider trades from Helus Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HELP

Score
MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

$HELPHighAI 8/10

Why is Helus Pharma stock tumbling today?

Helus Pharma (HELP) shares fell 25.4% in pre-market trading after reporting Phase 3 trial success for HLP003, a treatment for major depressive disorder, but missing Q2 earnings estimates by $0.68 per share. The stock declined despite meeting primary endpoints, with investors reacting to the earnings miss and broader market downturn.

Dow, S&P 500, Nasdaq Futures Edge Lower As Markets Brace For Nvidia Earnings, Anthropic IPO, Fed Minutes: SMMT, NBIS, HELP, MSTR In Focus

Nvidia's earnings and Anthropic's IPO are key market catalysts. Nvidia, led by interim CEO Kress, reports Q3 results on Nov. 17. Analysts expect robust demand metrics. Meanwhile, Anthropic's IPO could value the AI firm at $1.4T. Oil prices fell on Trump's Iran remarks. Summit Therapeutics (SMMT) dropped 20% after FDA rejection, Nebius (NBIS) fell 4% on weak results, Helus Pharma (HELP) rose 23% ahead of Phase 3 data, and MicroStrategy (MSTR) dropped 7% with Bitcoin.

Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances

Cybin (NASDAQ: HELP) expects Q4 Phase III data for its depression treatment HLP003, which showed significant symptom improvement in earlier studies. The company also plans a Phase II study for its anxiety treatment HLP004 in 2027. HLP003 has FDA Breakthrough Therapy designation, and Cybin aims for comparable efficacy and favorable tolerability.

Related tickers